Older HPV-Positive Oropharyngeal Cancer Patients Have High Treatment Tolerability

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video examines results of a study that looked at treatment tolerability in elderly patients with HPV-positive oropharyngeal squamous cell carcinoma.

In this video, Richard Bakst, MD, of the Icahn School of Medicine at Mount Sinai in New York, discusses a study that examined treatment tolerability and outcomes in elderly patients (65 years and older) with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.

Bakst presented the results of the study (abstract 2764) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content
The cumulative chronic grade 3 or higher toxicity rate was 3% in patients treated with de-escalated adjuvant radiotherapy vs 11% with standard of care therapy.

DART Therapy Exhibits Greater Tolerability in Oropharyngeal SCC

Roman Fabbricatore
September 9th 2025
Article
David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
September 9th 2025
Podcast
In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

Tim Cortese
September 9th 2025
Article
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Omar K. Abughanimeh, MBBS;Nicole A. Shonka, MD;Jane Meza, PhD;Lynette Smith, PhD;Irfan A. Vaziri, MD;Mehmet Sitki Copur, MD;Robin High, MBA;Kimberly Shields, BSN, RN;Holly DeSpiegelaere, BSN, RN;Anne Kessinger, MD;Apar Kishor Ganti, MD, MS
September 9th 2025
Article
Data from the RATIONALE-309 trial support the European Commission’s approval of frontline tislelizumab plus chemotherapy in this patient population.

Tislelizumab/Chemotherapy Earns EU Approval in Nasopharyngeal Carcinoma

Russ Conroy
September 9th 2025
Article
No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer

Roman Fabbricatore
September 9th 2025
Article